APA (7th ed.) Citation

He, C., Yu, J., Mao, S., Yang, S., Jiang, X., Huang, L., . . . Xiang, X. (2025). SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway. Clinical & Translational Medicine, 15(2), 1. https://doi.org/10.1002/ctm2.70231

Chicago Style (17th ed.) Citation

He, Chunxiao, et al. "SHP2 Inhibition and Adjuvant Therapy Synergistically Target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 Pathway." Clinical & Translational Medicine 15, no. 2 (2025): 1. https://doi.org/10.1002/ctm2.70231.

MLA (9th ed.) Citation

He, Chunxiao, et al. "SHP2 Inhibition and Adjuvant Therapy Synergistically Target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 Pathway." Clinical & Translational Medicine, vol. 15, no. 2, 2025, p. 1, https://doi.org/10.1002/ctm2.70231.